Advances in proteomic profiling of pediatric kidney diseases

Cummins, Timothy D.; Korte, Erik A.; Bhayana, Sagar; Merchant, Michael L.; Barati, Michelle T.; Smoyer, William E.; Klein, Jon B.

doi:10.1007/s00467-022-05497-2

Cited by 10 publications

(5 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most studies have been conducted on adults, and proteomics research in CKD has not been extensively transferred to the pediatric population [ 5 ]. This is the first study using PZP from proteomic profiling data to describe the upregulation of PZP in association with CVD markers, which supports the possibility that protein biomarkers may have clinical usefulness for discriminating CV risk in pediatric CKD [ 35 , 36 ].…”

Section: Discussionsupporting

confidence: 53%

Pregnancy Zone Protein as an Emerging Biomarker for Cardiovascular Risk in Pediatric Chronic Kidney Disease

Chen,

Liao,

Hsu

et al. 2023

JCM

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a significant cause of mortality and morbidity among children with chronic kidney disease (CKD). The causes of pediatric CKD differ from those in adults, as congenital anomalies in the kidney and urinary tract (CAKUT) are the leading causes in childhood. Identifying ideal markers of CVD risk early is crucial for CKD children to improve their care. Previously, we screened differentially expressed proteins in CKD children with or without blood pressure (BP) abnormalities and identified pregnancy zone protein (PZP). In 106 children and adolescents with CKD stages G1–G4, we analyzed plasma PZP concentration. The associations between PZP and ambulatory BP monitoring (ABPM) profile, parameters of cardiac and carotid ultrasounds, indices of arterial stiffness, and nitric oxide (NO) parameters were determined. We observed that PZP positively correlated with arterial stiffness indices, beta index, and pulse wave velocity in CAKUT. CKD children with abnormalities in ABPM and night dipping displayed a higher PZP concentration than those without. Additionally, the PZP level was positively correlated with NO bioavailability. In conclusion, our results suggest PZP has differential influences on cardiovascular risk in CAKUT and non-CAKUT children. Identification of this relationship is novel in the pediatric CKD literature.

show abstract

Section: Discussionsupporting

confidence: 53%

Pregnancy Zone Protein as an Emerging Biomarker for Cardiovascular Risk in Pediatric Chronic Kidney Disease

Chen,

Liao,

Hsu

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In paediatric oncology, proteogenomic studies are furthering our understanding of relapse and treatment resistance in children with acute myeloid leukaemia, providing new approaches to predict relapse during disease progression, novel biomarkers and new targets for novel drug therapies (Stratmann et al, 2022 ). Other areas where proteomics provides value to prediction, diagnostics and personalised interventions include chronic kidney disease and peritoneal dialysis in children (Cummins et al, 2022 ; Trincianti et al, 2022 ), drug metabolism and personalised dose optimisation in children (Streekstra et al, 2021 ; van Groen et al, 2022 ) and the use of multi-omics derived biomarkers to develop prediction models in children with asthma to guide therapy (Golebski et al, 2020 ; Kang et al, 2022 ). Proteomics either in isolation or part of a multi-omics approach has revolutionised our ability to develop individual disease profiling across multiple areas of paediatrics with new diagnostic, predictive and prognostic methodologies, and new targets for novel drug development.…”

Section: Developing Biomarkers and Targeted Therapies To Treat Childh...mentioning

confidence: 99%

Precision diagnostics in children

Dimitri¹

2023

Camb. prisms Precis. med.

View full text Add to dashboard Cite

Medical practice is transforming from a reactive to a pro-active and preventive discipline that is underpinned by precision medicine. The advances in technologies in such fields as genomics, proteomics, metabolomics, transcriptomics and artificial intelligence have resulted in a paradigm shift in our understanding of specific diseases in childhood, greatly enhanced by our ability to combine data from changes within cells to the impact of environmental and population changes. Diseases in children have been reclassified as we understand more about their genomic origin and their evolution. Genomic discoveries, additional 'Omics' data and advances such as optical genome mapping have driven rapid improvements in the precision and speed of diagnoses of diseases in children, and are now being incorporated into newborn screening, have improved targeted therapies in childhood, and have supported the development of predictive biomarkers to assess therapeutic impact and determine prognosis in congenital and acquired diseases of childhood.New medical device technologies are facilitating data capture at a population level to support higher diagnostic accuracy and tailored therapies in children according to predicted population outcome, and digital ecosystems now tailor therapies and provide support for their specific needs. By capturing biological and environmental data as early as possible in childhood, we can understand factors that predict disease or maintain health, and track changes across a more extensive longitudinal path. Data from multiple health and external sources over long time periods starting from birth or even in the in-utero environment will provide further clarity about how to sustain health and prevent or predict disease. In this respect, we will not only use data to diagnose disease, but precision diagnostics will aid the 'diagnosis of good health'. The principle of 'start early and gain more' will thus underpin the value of applying a personalised medicine approach early in life.

show abstract

“…So far, several disease-specific biomarkers have been identified, such as CD44 in membranous nephropathy, dipeptidase 1 (DPEP1) and apolipoproteins in focal glomerulosclerosis (FSGS), and the laminin G-like 3 (LG3) fragments of endorepellin in IgA nephropathy [ 110 , 111 ]. Although many studies have been carried out in adults, proteomic analysis of CKD has not widespread transferred into the pediatric realm [ 111 , 112 ]. Using isobaric tags for relative and absolute protein quantification (iTRAQ)-based proteomic analysis, one study identified 20 differentially expressed proteins associated with hypertension in children with CKD stages 1–4 [ 113 ].…”

Section: Cardiovascular Risks and Biomarkers In Pediatric Ckdmentioning

confidence: 99%

Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease

Tain

Hsu²

2022

Children

View full text Add to dashboard Cite

Hypertension is the most common complication of chronic kidney disease (CKD) in children, having a strong association with subsequential cardiovascular disease (CVD). In pediatric CKD, a considerable percentage of children with hypertension are undiagnosed or undertreated. Prior research has evaluated structural and functional markers of subclinical CVD and biomarkers in adults with CKD, while ideal biomarkers in pediatrics are still insufficiently studied. The ultimate goal of this review is to summarize what is currently known about state of hypertension, cardiovascular risk factors, and potential CVD markers/biomarkers in children with pre-dialysis CKD. We discuss omics-related biomarkers and the pathophysiologic processes of endothelial dysfunction, kidney injury, oxidative stress and inflammation that are classified by specific biomarkers. Moreover, we illustrate the existing challenges and highlight the paucity of pediatric CKD research to evaluate these CVD biomarkers for future clinical pediatric practice. Thus, achieving clinical utility of CVD biomarkers for use in pediatric CKD remains a significant challenge requiring additional efforts.

show abstract

Advances in proteomic profiling of pediatric kidney diseases

Cited by 10 publications

References 65 publications

Pregnancy Zone Protein as an Emerging Biomarker for Cardiovascular Risk in Pediatric Chronic Kidney Disease

Pregnancy Zone Protein as an Emerging Biomarker for Cardiovascular Risk in Pediatric Chronic Kidney Disease

Precision diagnostics in children

Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease

Contact Info

Product

Resources

About